China Pharmaceuticals Industry Profile - ISIC2423 (Related Reports)

China Pharmaceuticals Industry Profile - ISIC2423


September 7, 2013
28 Pages - SKU: BJZ5135798
License type:
Online Download      US $580.00
Global Site License      US $1,450.00
Atomic Spectroscopy Market by Technology ( X-Ray Fluorescence / Atomic Absorption / X-Ray Diffraction / ICP-MS ) & by Application ( Food & Beverage / Pharmaceutical / Industrial Chemistry / Biotechnology / Environment ) - Competitive Landscape - Global Fo
4/14/2014 | published by: MarketsandMarkets
Atomic Spectroscopy Market by Technology ( X-Ray Fluorescence / Atomic Absorption / X-Ray Diffraction / ICP-MS ) & by Application ( Food & Beverage / Pharmaceutical / Industrial Chemistry / Biotechnology / Environment ) -  |  read more...
$4,650.00
Greece Pharmaceuticals and Healthcare Report Q2 2014
4/23/2014 | published by: Business Monitor International
Greece Pharmaceuticals and Healthcare Report Q2 2014 BMI View: Despite the Greek economy's expected return to growth in 2014, we expect no lessening in thepressures on the Greek pharmaceutical and healthcare sectors over the medium- to  |  read more...
$1,295.00
South Africa Pharmaceuticals and Healthcare Report Q2 2014
4/23/2014 | published by: Business Monitor International
South Africa Pharmaceuticals and Healthcare Report Q2 2014 BMI View: South Africa is the best investment opportunity for multinational drugmakers seeking to enterthe African market - boasting the largest medicines market on the continent and poised  |  read more...
$1,295.00
Cambodia and Laos Pharmaceuticals and Healthcare Report Q2 2014
4/16/2014 | published by: Business Monitor International
Cambodia and Laos Pharmaceuticals and Healthcare Report Q2 2014 BMI View: Low health and pharmaceutical expenditures will continue to limit the attractiveness of thepharmaceutical market in Cambodia. Given such a profile, the country will present more  |  read more...
$1,295.00
Bahrain Pharmaceuticals and Healthcare Report Q2 2014
4/16/2014 | published by: Business Monitor International
Bahrain Pharmaceuticals and Healthcare Report Q2 2014 BMI View: This quarter has seen the beginning of a multi-phased plan by the National Health RegulatoryAuthority to significantly reduce medicine prices in the country, signalling a potential advancement  |  read more...
$1,295.00
Denmark Pharmaceuticals and Healthcare Report Q2 2014
4/16/2014 | published by: Business Monitor International
Denmark Pharmaceuticals and Healthcare Report Q2 2014 BMI View: Although Denmark's pharmaceutical market is relatively small compared to other WesternEuropean countries, the demand for high quality healthcare will remain elevated by an increasing andageing population. This  |  read more...
$1,295.00
Iraq Pharmaceuticals and Healthcare Report Q2 2014
4/16/2014 | published by: Business Monitor International
Iraq Pharmaceuticals and Healthcare Report Q2 2014 BMI View: The projected growth of Iraq's pharmaceutical market in 2014 and 2015 is linked to an oildriveneconomic expansion, which is dependent on the government's ability to represent and  |  read more...
$1,295.00
Lithuania Pharmaceuticals and Healthcare Report Q2 2014
4/16/2014 | published by: Business Monitor International
Lithuania Pharmaceuticals and Healthcare Report Q2 2014 BMI View: We expect the Lithuanian pharmaceutical market to post a five-year compound annual growthrate (CAGR) of 4.4%, rising to a value of LTL2.16bn (US$751mn) in 2018. While double-digit  |  read more...
$1,295.00
Sri Lanka Pharmaceuticals and Healthcare Report Q2 2014
4/16/2014 | published by: Business Monitor International
Sri Lanka Pharmaceuticals and Healthcare Report Q2 2014 BMI View: A better-than-expected outlook for Sri Lanka's economy has led us to upwardly revise ourpharmaceutical and healthcare forecasts. The government has introduced price controls on wholesale andretail  |  read more...
$1,295.00
Venezuela Pharmaceuticals and Healthcare Report Q2 2014
4/16/2014 | published by: Business Monitor International
Venezuela Pharmaceuticals and Healthcare Report Q2 2014 BMI View: Foreign currency controls and drug price cuts will continue to affect pharmaceutical companies'profitability, with the currency devaluation and high inflation exacerbating the situation. A closerelationship and effective  |  read more...
$1,295.00